布拉氏酵母菌 CNCM I-745 在非甾体抗炎药诱发肠病实验模型中的保护作用。

IF 3 4区 医学 Q2 MICROBIOLOGY
E Simon O'Brien, A Robert, D Gauthier, A Le Cavorzin, J Planchais, X Roux, M Verleye, V Castagné
{"title":"布拉氏酵母菌 CNCM I-745 在非甾体抗炎药诱发肠病实验模型中的保护作用。","authors":"E Simon O'Brien, A Robert, D Gauthier, A Le Cavorzin, J Planchais, X Roux, M Verleye, V Castagné","doi":"10.3920/BM2023.0003","DOIUrl":null,"url":null,"abstract":"<p><p>Nonsteroidal anti-inflammatory drugs (NSAIDs) induce a broad spectrum of gastro-intestinal adverse effects, including ulceration and bleeding. The pathophysiology of NSAID enteropathy is complex and incompletely understood, but some evidence showed that NSAIDs impair the intestinal barrier and cause a gut dysbiosis. Identifying new treatments aiming to reverse or attenuate NSAID-induced adverse effects would have a significant impact on a high number of patients. The aim of this work is to assess the effects of the probiotic yeast Saccharomyces boulardii CNCM I-745 (Sb) on a model of NSAID-induced enteropathy. Four groups of mice were tested: Control, Indomethacin, Sb, and Sb + Indomethacin. A clinical score was evaluated throughout the experiment. Faecal calprotectin, microbiota and haemoglobin analyses were performed. At the end of the treatments, the small intestine, colon, and caecum lengths, and intestinal permeability were measured. Sections of ileum and jejunum were observed to assess a histological score and ileal cytokines were measured by immunoassay. Indomethacin-treated animals showed an increase in their clinical scores, reflecting a worsening of their general state. Mice co-treated with Sb and indomethacin displayed an improvement of their clinical score in comparison with mice treated with indomethacin alone. Sb prevented the indomethacin-induced shortening of the small intestine and caecum, and significantly attenuated the severity of intestinal lesions. Sb also prevented the increase in faecal calprotectin, reduced faecal haemoglobin, and prevented the increase of intestinal permeability in mice treated with indomethacin. Sb also counteracted the increase of faecal bacteria associated with the pathogenesis of NSAID-enteropathy. In conclusion, our results show a protective effect of Sb in a model of indomethacin-induced enteropathy. Sb improved the intestinal barrier function and exerted a positive action on gut microbiota composition.</p>","PeriodicalId":8834,"journal":{"name":"Beneficial microbes","volume":" ","pages":"239-253"},"PeriodicalIF":3.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Protective effects of Saccharomyces boulardii CNCM I-745 in an experimental model of NSAID-induced enteropathy.\",\"authors\":\"E Simon O'Brien, A Robert, D Gauthier, A Le Cavorzin, J Planchais, X Roux, M Verleye, V Castagné\",\"doi\":\"10.3920/BM2023.0003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Nonsteroidal anti-inflammatory drugs (NSAIDs) induce a broad spectrum of gastro-intestinal adverse effects, including ulceration and bleeding. The pathophysiology of NSAID enteropathy is complex and incompletely understood, but some evidence showed that NSAIDs impair the intestinal barrier and cause a gut dysbiosis. Identifying new treatments aiming to reverse or attenuate NSAID-induced adverse effects would have a significant impact on a high number of patients. The aim of this work is to assess the effects of the probiotic yeast Saccharomyces boulardii CNCM I-745 (Sb) on a model of NSAID-induced enteropathy. Four groups of mice were tested: Control, Indomethacin, Sb, and Sb + Indomethacin. A clinical score was evaluated throughout the experiment. Faecal calprotectin, microbiota and haemoglobin analyses were performed. At the end of the treatments, the small intestine, colon, and caecum lengths, and intestinal permeability were measured. Sections of ileum and jejunum were observed to assess a histological score and ileal cytokines were measured by immunoassay. Indomethacin-treated animals showed an increase in their clinical scores, reflecting a worsening of their general state. Mice co-treated with Sb and indomethacin displayed an improvement of their clinical score in comparison with mice treated with indomethacin alone. Sb prevented the indomethacin-induced shortening of the small intestine and caecum, and significantly attenuated the severity of intestinal lesions. Sb also prevented the increase in faecal calprotectin, reduced faecal haemoglobin, and prevented the increase of intestinal permeability in mice treated with indomethacin. Sb also counteracted the increase of faecal bacteria associated with the pathogenesis of NSAID-enteropathy. In conclusion, our results show a protective effect of Sb in a model of indomethacin-induced enteropathy. Sb improved the intestinal barrier function and exerted a positive action on gut microbiota composition.</p>\",\"PeriodicalId\":8834,\"journal\":{\"name\":\"Beneficial microbes\",\"volume\":\" \",\"pages\":\"239-253\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Beneficial microbes\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3920/BM2023.0003\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Beneficial microbes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3920/BM2023.0003","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

非甾体抗炎药(NSAIDs)会引起一系列胃肠道不良反应,包括溃疡和出血。非甾体抗炎药(NSAID)肠道病的病理生理学非常复杂,而且尚未完全清楚,但有证据表明,非甾体抗炎药(NSAID)会损害肠道屏障并导致肠道菌群失调。确定旨在逆转或减轻非甾体抗炎药引起的不良反应的新疗法将对大量患者产生重大影响。这项工作的目的是评估布拉氏酵母菌 CNCM I-745 (Sb) 对非甾体抗炎药诱发肠病模型的影响。测试了四组小鼠:对照组、吲哚美辛组、Sb 组和 Sb + 吲哚美辛组。在整个实验过程中对临床评分进行评估。还进行了粪便钙蛋白、微生物群和血红蛋白分析。治疗结束时,测量小肠、结肠和盲肠的长度以及肠道通透性。观察回肠和空肠切片以评估组织学评分,并用免疫测定法测定回肠细胞因子。用吲哚美辛治疗的动物的临床评分上升,反映出它们的总体状况恶化。与单独使用吲哚美辛的小鼠相比,联合使用 Sb 和吲哚美辛的小鼠的临床评分有所提高。蔗糖素能防止吲哚美辛引起的小肠和盲肠缩短,并显著减轻肠道病变的严重程度。蔗糖素还能防止吲哚美辛引起的小鼠粪便钙蛋白的增加,降低粪便血红蛋白,并防止肠道渗透性的增加。Sb 还能抵消与非甾体抗炎药肠病发病机制相关的粪便细菌的增加。总之,我们的研究结果表明,在吲哚美辛诱发的肠病模型中,Sb 具有保护作用。Sb 可改善肠道屏障功能,并对肠道微生物群的组成产生积极作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Protective effects of Saccharomyces boulardii CNCM I-745 in an experimental model of NSAID-induced enteropathy.

Nonsteroidal anti-inflammatory drugs (NSAIDs) induce a broad spectrum of gastro-intestinal adverse effects, including ulceration and bleeding. The pathophysiology of NSAID enteropathy is complex and incompletely understood, but some evidence showed that NSAIDs impair the intestinal barrier and cause a gut dysbiosis. Identifying new treatments aiming to reverse or attenuate NSAID-induced adverse effects would have a significant impact on a high number of patients. The aim of this work is to assess the effects of the probiotic yeast Saccharomyces boulardii CNCM I-745 (Sb) on a model of NSAID-induced enteropathy. Four groups of mice were tested: Control, Indomethacin, Sb, and Sb + Indomethacin. A clinical score was evaluated throughout the experiment. Faecal calprotectin, microbiota and haemoglobin analyses were performed. At the end of the treatments, the small intestine, colon, and caecum lengths, and intestinal permeability were measured. Sections of ileum and jejunum were observed to assess a histological score and ileal cytokines were measured by immunoassay. Indomethacin-treated animals showed an increase in their clinical scores, reflecting a worsening of their general state. Mice co-treated with Sb and indomethacin displayed an improvement of their clinical score in comparison with mice treated with indomethacin alone. Sb prevented the indomethacin-induced shortening of the small intestine and caecum, and significantly attenuated the severity of intestinal lesions. Sb also prevented the increase in faecal calprotectin, reduced faecal haemoglobin, and prevented the increase of intestinal permeability in mice treated with indomethacin. Sb also counteracted the increase of faecal bacteria associated with the pathogenesis of NSAID-enteropathy. In conclusion, our results show a protective effect of Sb in a model of indomethacin-induced enteropathy. Sb improved the intestinal barrier function and exerted a positive action on gut microbiota composition.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Beneficial microbes
Beneficial microbes MICROBIOLOGY-NUTRITION & DIETETICS
CiteScore
7.90
自引率
1.90%
发文量
53
审稿时长
>12 weeks
期刊介绍: Beneficial Microbes is a peer-reviewed scientific journal with a specific area of focus: the promotion of the science of microbes beneficial to the health and wellbeing of man and animal. The journal contains original research papers and critical reviews in all areas dealing with beneficial microbes in both the small and large intestine, together with opinions, a calendar of forthcoming beneficial microbes-related events and book reviews. The journal takes a multidisciplinary approach and focuses on a broad spectrum of issues, including safety aspects of pro- & prebiotics, regulatory aspects, mechanisms of action, health benefits for the host, optimal production processes, screening methods, (meta)genomics, proteomics and metabolomics, host and bacterial physiology, application, and role in health and disease in man and animal. Beneficial Microbes is intended to serve the needs of researchers and professionals from the scientific community and industry, as well as those of policy makers and regulators. The journal will have five major sections: * Food, nutrition and health * Animal nutrition * Processing and application * Regulatory & safety aspects * Medical & health applications In these sections, topics dealt with by Beneficial Microbes include: * Worldwide safety and regulatory issues * Human and animal nutrition and health effects * Latest discoveries in mechanistic studies and screening methods to unravel mode of action * Host physiology related to allergy, inflammation, obesity, etc. * Trends in application of (meta)genomics, proteomics and metabolomics * New developments in how processing optimizes pro- & prebiotics for application * Bacterial physiology related to health benefits
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信